Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 janv. 2025 10h25 HE | Source: Cytosurge AG

Cytosurge Announces Strategic Leadership Transition

Cytosurge appoints Simon Egli as CEO; co-founder Pascal Behr transitions to Board to ensure strategic guidance and growth.
15 oct. 2024 09h00 HE | Source: Cytosurge AG; Lexogen GmbH

Cytosurge and Lexogen Partner to Advance Live-Cell Sequencing

Cytosurge and Lexogen partner to advance Live-seq, integrating FluidFM® and LUTHOR HD to enable scalable, live-cell transcriptomics with high sensitivity.
29 mai 2024 08h30 HE | Source: Cytosurge AG

Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication

CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
29 mai 2024 02h30 HE | Source: Cytosurge AG

Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication

CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.